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Summary  
Genomic integrity is constantly threatened by problems encountered by the replication fork. BRCA1, 
BRCA2 and a subset of Fanconi Anaemia proteins protect stalled replication forks from nuclease 
degradation through pathways involving RAD51. The contribution and regulation of BRCA1 in 
replication fork protection, and whether this relates to, or differs from, BRCA1’s role in homologous 
recombination (HR) is not clear. Here we show that the canonical BRCA1-PALB2 interaction is not 
required for fork protection but instead BRCA1-BARD1 is regulated through a conformational change 
mediated by the phosphorylation-directed prolyl isomerase, PIN1. PIN1 activity enhances BRCA1-
BARD1 interaction with RAD51 and consequently RAD51’s presence at stalled replication structures. 
We identify patient missense variants in the regulated BRCA1-BARD1 regions which show poor 
nascent strand protection but remain proficient for HR, defining novel domains required for fork 
protection associated with cancer development. Together these findings reveal a previously 
unrecognised pathway that governs BRCA1-mediated replication fork protection.  
 
Main Text 
Fork progression can be slowed by conflicts with transcription, deoxyribonucleotide (dNTP) shortage 
or by difficult to replicate sequences, frequently causing fork stalling1. In order to prevent stalled 
forks collapsing into DNA double strand breaks (DSBs), a number of responses are elicited including 
fork remodelling and subsequent nascent strand protection. Agents that cause replicative stress or 
compromise DNA Polymerase-α function result in a proportion of forks reversing (reviewed in2,3). 
The regressed arm of nascent DNA in reversed forks resembles a single-ended DNA DSB which is 
protected from excessive resection by RAD51. Several factors contribute to RAD51-mediated fork 
protection including BRCA1/2, FANCA/D2, RAD51 paralogs, BOD1L, SETD1A, WRNIP and Abro1 2. 
One emerging theme is that stabilisation of the RAD51-nucleofilament is critical for protection of 
stalled forks4-6. RAD51 mutants that show increased dissociation are compromised in their ability to 
prevent fork degradation6-8 while RAD51-ssDNA stabilising factors, such as BOD1L, promote fork 
protection9. Other factors such as RADX, compete with, or dissociate, RAD51 so that their depletion 
rescues fork protection of BRCA-deficient cells10,11. Failure to protect stalled forks is associated with 
genome instability.  Restoration of replication fork protection in BRCA-deficient cells is linked to 
chemotherapy resistance in some cell types and contexts12-14. Thus further mechanistic 
understanding is needed to inform cancer patient care. 
BRCA1 is found at ongoing and stalled replication forks15,16 and, like BRCA2, contributes to RAD51-
mediated protection of stalled forks from MRE11-dependent degradation17. However, how BRCA1 
contributes to fork protection is unclear. Here we show BRCA1 promotes the protection of nascent 
DNA at stalled replication forks independently of the canonical BRCA1-PALB2 interaction. We find 
that an enhanced, direct interaction between BRCA1-BARD1 and RAD51 is associated with nascent 
strand protection and this is dependent on the activity of the phosphorylation-directed prolyl 
isomerase, PIN1. We identify BRCA1 and BARD1 regions required for fork protection and find patient 
variants associated with familial and sporadic cancer which inhibit fork protection.  
 
pS114-BRCA1 promotes fork protection  
During homologous recombination (HR) repair of DNA double-strand breaks (dsDNA breaks), BRCA1-
BARD1 regulates RAD51 localisation and loading through PALB2-BRCA218-20 but it is unclear if BRCA1 
acts through this pathway in replication fork protection. We examined nascent DNA sequentially 
labelled with CldU-IdU at hydroxyurea (HU) stalled forks (5 mM HU, 3 hours)5 17  in PALB2 or BRCA1-
depleted cells and both conditions showed decreased IdU/CldU ratios consistent with defective fork 
protection (Extended Data Fig 1a-c). Mutations in BRCA1 (M1411T) or PALB2 (ΔNT) coiled-coil motifs 
prevent direct interaction, fail to support HR-repair and show increased sensitivity to the inter-
strand cross-linker Cisplatin19,20 (Extended Data Fig 1d-i). While both Flag-EGFP-M1141T-BRCA1 and 
ΔNT-PALB2 complemented cells showed increased fork stalling and defects in replication fork restart 
following HU exposure, these mutants were proficient in stalled replication fork protection 
(Extended data Fig 1j-o). Thus fork protection is independent of the canonical BRCA1-PALB2 
interaction. 
BRCA1 and BARD1 interact directly with RAD5121,22 and mutation of BARD1 residues F133, D135 and 
A136 (F133A-D135A-A136E, termed AAE) disrupts the BARD1-RAD51 interaction causing reduced 
resistance to mitomycin C21, Olaparib and HU (Extended Data Fig 2a-b). Complementation with RFP-
Flag-AAE-BARD1 did not support protection of nascent strands unlike cells complemented with RFP-
Flag-WT-BARD1 or the ubiquitin-ligase deficient mutant RFP-Flag-R99E-BARD123 (Extended Data Fig 
2c-f). Thus protection of stalled replication forks requires the RAD51 binding site region in BARD1 
but not heterodimer ligase activity. 
BRCA1 and BARD1 are phosphorylated at residues potentially structurally close to the BARD1-RAD51 
interaction site: S148-BARD124 and S114-BRCA125. Substitution of these sites to alanines (Flag-EGFP-
S114A-BRCA1 or RFP-Flag-S148A-BARD1) reduced IdU/CldU ratios and CldU tract lengths following 
HU-treatment: both assays giving results consistent with defective fork protection (Fig 1a-b, 
Extended Data Fig 3a-c). In contrast, mutation to the phospho-mimic aspartate (D) supported fork 
protection in cells complemented with Flag-EGFP-S114D-BRCA1 but not RFP-Flag-S148D-BARD1 (Fig 
1a-b, Extended Data Fig 3d-e), supporting a role for BRCA1 phosphorylation in fork protection. 
Immunoblotting of RFP-Flag-S148D-BARD1 revealed the presence of a smaller BARD1 band 
(Extended Data Fig 3e), suggesting cleavage of this mutant. 
Flag-EGFP-S114A-BRCA1 and Flag-EGFP-WT-BRCA1 showed similar levels of recruitment to active 
replication sites, comparable interactions with BARD1, and restoration of ongoing forks and fork 
restart after 3 hour exposure to 5 mM HU (Extended Data Fig 3f-i), suggesting that the S114-site is 
not significant to these aspects of replication stress.  Mirin inhibition of MRE11 3’-5’ nuclease activity 
in BRCA1/2 deficient cells restores fork protection17, and likewise Mirin-treatment restored long 
CldU tract lengths in Flag-EGFP-S114A-BRCA1 complemented cells (Extended Data Fig 3j-k), 
implicating the S114-site in the protection of nascent DNA from nuclease activity. 
We generated an antibody against phosphorylated-S114 BRCA1 peptide (pS114) which detected 
immunoprecipitated Flag-EGFP-WT-BRCA1 but not Flag-EGFP-S114A-BRCA1 (Fig 1c). Intriguingly,  
BRCA1 phospho-S114  lies within an S-P motif which is a minimal consensus sequence for the 
phospho-peptidyl-prolyl isomerase (PPIase) PIN1, and BRCA1-BARD1 have previously been enriched 
from lysates using recombinant PIN126. We confirmed this interaction by immunoprecipitation of 
BARD1-BRCA1-PIN1 (Fig 1d). A GST-fusion of the PIN1 WW phospho-binding domain (GST-WW), but 
not a GST-W34A-WW mutant deficient in phospho-binding27, could purify Flag-EGFP-WT-BRCA1 and 
Flag-EGFP-S114D-BRCA1 whereas neither GST-WW nor GST-W43A-WW purified Flag-EGFP-S114A-
BRCA1 (Fig 1e and Extended Data Fig 4a-c). Furthermore, the interaction between exogenous or 
endogenous BRCA1 with recombinant GST-WW was increased following HU-treatment and lost 
following treatment of the cell lysate with phosphatase (Fig 1f, Extended Data Fig 4d-e). While RFP-
Flag-WT-BARD1 was also purified by GST-WW, this interaction was not lost on mutation of the 
RAD51 proximal phosphorylation site at S148 (RFP-Flag-S148A-BARD1) (Extended Data Fig 4f). 
Together these data suggest that BRCA1 phosphorylation at S114 is upregulated in response to HU 
and promotes the ability of the GST-PIN1-WW domain to purify BRCA1. 
To identify kinase(s) responsible for phosphorylating S114-BRCA1, we performed a targeted kinase 
inhibitor screen to members of the proline-directed kinase superfamily. Treatment with the CDK1/2 
inhibitor, Roscovitine, but not inhibitors to JNK1/2 (SP600125), DYRKs (INDY), MEK1/2 (U0126) or 
GSK (Inhibitor IX), reduced the ability of GST-WW to enrich BRCA1 from cell lysates (Extended Data 
Fig 4g-h). Indeed, the BRCA1 S114 site lies within a loose CDK1/2 consensus site (S-P-x-x-x-K). 
Treatment of cells with the CDK1 inhibitor (RO-3306) or with CDK1 siRNA reduced the ability of the 
pS114 antibody or the GST-WW domain to purify BRCA1 from cell lysates (Fig 1g, Extended Data Fig 
4i). Similarly incubation of recombinant CDK1/Cyclin A2 or CDK2/Cyclin A, but not CDK9/Cyclin K 28, 
with recombinant His-BRCA11-300-BARD126-142 resulted in phosphorylation of WT-BRCA1 at S114 
(Extended Data Fig  4j-l). These data suggest that CDK1/2-mediated phosphorylation are likely to be 
the dominant kinases responsible for S114-BRCA1 modification. 
Given the increase in pS114-BRCA1 following HU-treatment in cells, we next examined whether 
pS114-BRCA1 locates to sites of stalled replication forks. Using the proximity ligation assay (PLA) we 
assessed potential proximity between EdU incorporated at ongoing forks, or at forks stalled by HU-
treatment, with the phospho-specific pS114-BRCA1 antibody. We observed a BRCA1-dependent PLA 
signal in HU-treated cells which was partially reduced in cells treated with a phosphatase (CIP) or the 
CDK1/2 inhibitor, Roscovitine (Fig 1h-i). Together these data support the view that pS114-BRCA1 is 
localised to stalled replication forks.  
 
PIN1 regulates BRCA1-BARD1  
PIN1 is enriched in isolated proteins on nascent DNA (iPOND) following treatment with HU10. We 
tested whether fork protection requires PIN1 and found that either PIN1 inhibition with Juglone, or 
PIN1-depletion, led to shortened CldU tracts and reduced IdU/CldU ratios following HU-treatment 
consistent with a fork protection defect (Fig 2a-b, Extended Data Fig 5a). Co-depletion of PIN1 with 
BRCA1 or BARD1 did not reduce nascent strand lengths further (Fig 2a-b, Extended Data Fig 5b-c). 
We saw no gross impact on BRCA1 or BARD1 protein levels following PIN1 depletion (Fig 2b, 
Extended Data Fig 5c-e). 
In folded proteins, peptide bonds preceding residues other than proline (non-prolyl bonds) 
overwhelmingly favour the trans form, and cis bonds are rare in folded proteins29. Due to the 
physical constraints of proline’s unique 5-membered ring, peptide bonds preceding proline (prolyl 
bonds) may adopt the cis conformation30. PIN1 is the only phospho-targeted PPIase that specifically 
recognises phospho-S/T-P motifs31 before catalysing a cis-trans conformational change of the 
peptidyl-prolyl bond32-35. To examine requirements for the trans-isomer one can substitute the 
target proline with another amino acid to favour the probability of the trans form36,37. We mutated 
Flag-EGFP-BRCA1 P115 to an alanine or a cysteine and found both mutants maintained fork 
protection (Fig 2d-e, Extended Data Fig 5f-g), suggesting proline mutation or trans-isomerisation at 
this position is not deleterious. Importantly, inclusion of P115A or P115C with the S114A mutation 
restored IdU/CldU ratios in BRCA1-depleted cells to control levels (Fig 2d-e, Extended Data Fig 5f-g), 
showing that P115A or P115C can overcome the requirement for serine at 114. In cells co-depleted 
for BRCA1 and PIN1 we similarly found expression of Flag-EGFP-P115A-BRCA1 or Flag-EGFP-S114A-
P115A-BRCA1, resulted in IdU/CldU ratios close to 1, compared to cells with Flag-EGFP-WT-BRCA1 
expression (ratios of 0.5) (Fig 2f-g). Thus the requirement for PIN1 in fork protection can be largely 
overcome by expression of BRCA1 mutant at position P115. 
  
BRCA1 isomerisation aids RAD51 binding  
Both BRCA1 and BARD1 have RING-proximal regions significant to fork protection: BRCA1 contains 
the S114-P115 regulatory region and BARD1 contains a required RAD51 binding region. Given the 
potential physical proximity of these regions we next asked whether PIN1 influences BRCA1-BARD1-
RAD51 interaction. Using recombinant proteins we first incubated WT His-BRCA11-500-BARD127-327 and 
phospho-mimic S114D His-BRCA11-500-BARD127-327 heterodimers with full length GST-PIN1 before 
incubating with purified, recombinant RAD51. Then we used His-pull down to examine the BRCA1-
BARD1-RAD51 interaction. Only the heterodimer that included the BRCA1 phospho-mimic, S114D 
and which had been incubated with GST-PIN1 was able to bind RAD51 (Extended Data Fig 6a-b). To 
test this further we next phosphorylated His-BRCA11-300-BARD127-142 with CDK1/Cyclin A2 (Extended 
Data Fig 4j-l) and incubated this with either full length GST-WT-PIN1 or GST-C113S-PIN1 (Fig 3a and 
Extended Data Fig 6b). C113S inhibits PIN1-mediated isomerisation38, but does not prevent the 
interaction of PIN1 with its target proteins39. Only phosphorylated His-BRCA11-300-BARD126-142 which 
had been incubated with active GST-WT-PIN1 was able to bind RAD51 (Fig 3a). These data confirm 
the requirement for phosphorylation and demonstrate the need for PIN1-activity in enhancing 
RAD51 binding to the BRCA1-BARD1 heterodimer. Finally, we generated recombinant purified WT 
and P115A His-BRCA11-500-BARD126-327 (Extended Data Fig 6c) and incubated these with RAD51 in the 
absence of PIN1. We found a greater interaction with RAD51 when the BRCA1-BARD1 heterodimer 
bearing P115A-BRCA1 was used (Fig 3b). These data are consistent with the finding that PIN1 activity 
is needed to increase RAD51 binding and also suggest that PIN1 presence is not directly needed to 
contribute to heterodimer-RAD51 interaction.  
Since BRCA1 also contains a RAD51 binding region (aa708-1064), the impact of regulation around 
BRCA1 residue 115 may differ in the context of full-length proteins. Using full length BRCA1-BARD1 
purified from insect cells we found that both WT and P115A-BRCA1-BARD1 interacted with RAD51 
but the interaction was enhanced with heterodimers containing P115A-BRCA1 (Extended Data Fig 
6d-e). Moreover immunoprecipitated P115A-BRCA1-BARD1 from mammalian cells showed a similar 
enrichment for RAD51 (~1.5-fold) (Extended Data Fig 6f-g). We exposed length recombinant WT-
BRCA1-BARD1 to limited proteolysis and found that the rate of BRCA1 digestion was virtually 
unchanged by inclusion of P115A mutation. However, remarkably, the BARD1 digestion rate was 
increased by inclusion of P115A-BRCA1 (Fig 3c-d, Extended Data Fig 6h), indicating improved 
accessibility to BARD1 in the presence of P115A-BRCA1.  
We addressed whether mutations of the S114-P115-BRCA1 site influence RAD51 presence at 
nascent DNA following HU-treatment4,5 using the proximity linked ligation assay (PLA)40. Flag-EGFP-
S114A-BRCA1 complemented cells were unable to restore WT-levels of RAD51-EdU PLA-foci in 
contrast to cells complemented with Flag-EGFP-S114A-P115A-BRCA1 (Fig 3e, Extended Data Fig 6i). 
These data suggest that the P115A mutant in BRCA1 overcomes the requirement for a functional 
phosphorylation site, or serine, at S114 to promote RAD51 accumulation at nascent DNA. Likewise, 
in cells co-depleted for BRCA1 and PIN1 the RAD51-EdU PLA foci levels were restored by 
complementation of Flag-EGFP-S114A-P115A-BRCA1 but not Flag-EGFP-S114A-BRCA1 (Fig 3f). Thus 
in cells PIN1’s contribution to RAD51 recruitment at stalled forks can be overcome by P115A-BRCA1 
expression.  
 
Isomerisation promotes genome stability  
Brca1 deficient murine B-cells manipulated to enable fork protection, while still retaining HR-
deficiency, exhibit reduced chromosome aberrations following PARPi/Cisplatin treatment and show 
resistance to HU12. This suggests loss of fork protection capability alone could be associated with 
altered responses to therapeutic agents. Cells complemented with Flag-EGFP-S114A-BRCA1 were 
resistant to PARP inhibitors (Olaparib, Veliparib and 4AN) and formed RAD51 foci after Olaparib 
treatment, but were sensitive to 16-hour treatment with replication stress-inducing agents (HU and 
Aphidicolin) (Fig 4a-b, Extended Data Fig 7a-g). Since prolonged HU treatment causes fork collapse 
and double strand breaks41, we also assessed colony survival in response to conditions that promote 
fork stalling but not collapse (3 hours, 5 mM HU)41,42. Intriguingly, even in asynchronous cells treated 
with short-term HU, Flag-EGFP-S114A-BRCA1 complemented cells showed reduced colony formation 
(Fig 4b-c). Moreover inclusion of the P115A mutation on the S114A background was sufficient to 
rescue the S114A defect in survival seen in response to both 3 hour and 16-hour treatment with HU 
(Fig 4a-c). 
These data led us to investigate chromosome stability. Depletion of BRCA1 increased both the 
average number of breaks per metaphase and the percentage of metaphases with radial 
chromosomes (Fig 4d-f). Strikingly complementation with Flag-EGFP-S114A-BRCA1 restored the 
percentage of radial chromosomes, but not chromosome breaks, to control and Flag-EGFP-WT-
BRCA1 levels, while complementation with Flag-EGFP-S114A-P115A-BRCA1 both phenotypes to 
control levels (Fig 4d-F). These data build a view in which the S114-P115 region of BRCA1 supports 
nascent DNA protection, the prevention of chromosome breakages, and HU resistance.  
 
Constitutive P115A-BRCA1 is genotoxic  
We next questioned the necessity for such a complex mechanism of BRCA1-BARD1 regulation and 
whether the constitutive presence of a heterodimer primed for increased RAD51 interaction and 
fork protection is deleterious. We constitutively expressed Flag-EGFP-WT-BRCA1 Vs Flag-EGFP-
P115A-BRCA1 in cells over several days. Cells were taken at 4 day intervals and assessed for BRCA1 
expression, γH2AX foci as a marker of DNA damage signalling, and chromosome integrity in 
metaphase spreads (Fig 5a-d, Extended Data Fig 8a). Flag-EGFP-P115A-BRCA1 cells showed a 
significant increase in γH2AX staining and the number of breaks per metaphase compared to 
matched Flag-EGFP-WT-BRCA1 cells (Fig 5a-d and Extended Data Fig 8a). Thus long-term exposure to 
P115A-BRCA1 promotes an increased rate of DNA damage accumulation. 
 
Fork protection in patient variants  
Somatic and germ line genetic variants associated with cancer have been found within or close to 
the BRCA1 S114-P115 phosphorylation-isomerisation site and the BARD1-RAD51 binding region 
(https://research.nhgri.nih.gov/bic/43,44 45). To assess whether these affect replication fork 
protection, we generated point mutations corresponding to missense variants with a high Grantham 
difference and low variance (Fig 6a-b). BRCA1 patient variants S114P, R133C, Y179C, S184C, S256Y, 
but not Y101N, and BARD1 variants K144N and F147C, but not D135Y, showed reduced IdU/CldU 
ratios compared to controls consistent with a fork protection defect (Fig 6c-f). Moreover all mutants 
that showed a fork protection defect, also showed increased sensitivity to HU, while those that were 
proficient in fork protection did not (Fig 6g-i). 
The S114A-BRCA1 mutation supports several aspects of BRCA1 function: it prevents quadra-radial 
formation thought to represent toxic-NHEJ of cells deficient in HR-repair46, allows RAD51 foci, and 
supports PARPi resistance and replication restart (Fig 4d-f, Extended Data Fig 3i and 7b-g). These 
features suggest no significant role for the mutation in reducing HR repair proficiency. To address 
whether patient variants close to the S114-P115-BRCA1 and RAD51-BARD1 interaction regions show 
features of a recombination defect we examined complemented cells for RAD51 foci in S-phase cells 
after irradiation, cisplatin sensitivity and sensitivity to both short term (2 hour) and continuous 
exposure to Olaparib. Where possible cells expressing patient variants were also assessed for repair 
of an integrated HR-substrate following enzymatic generation of a DNA DSB (Extended Data Figs 9-
10 and summarised in Extended Data Table 1). Of those BRCA1 variants that showed poor fork 
protection and HU sensitivity S114P-BRCA1 and R133C-BRCA1 were not sensitive to continuous 
exposure to Cisplatin nor to short or continuous exposure to Olaparib and showed near WT-levels of 
RAD51 foci after Ionising Radiation (IR) (Extended Data Fig 9a-f). Of the BARD1 variants that showed 
poor fork protection and HU sensitivity K144N-BARD1 and F147C-BARD1 exhibited resistance to 
either length of Olaparib exposure, had near WT levels of RAD51 foci and showed resistance to all 
but the highest concentrations of Cisplatin. In addition, all BARD1 patient variants restored WT levels 
of HR in U20S DR-GFP reporter cells depleted for BARD1 (Extended Data Fig 10a-f).  
 
Discussion 
Our data reveals a direct function for BRCA1 in fork protection that is separate from the canonical 
PALB2-BRCA2 recruitment. Instead we propose a new model of BRCA1-BARD1-RAD51 regulation and 
identify post-translational modifications of BRCA1 upregulated by HU-treatment required for fork 
protection. Our findings support a model in which CDK1/2-PIN1 regulated conformational change 
results in an improved interface between BRCA1-BARD1 and RAD51 (Extended Data Fig 11). While 
PIN1 activity is capable of disrupting dimers and aggregates and driving interactions specific for cis or 
trans conformations47,48, this mechanism of isomerisation on one partner of a heterodimer 
promoting improved protein-protein interactions mediated by the other partner, appears unique. 
The cancer-associated patient mutations we identify in BRCA1-BARD1, extend the known regions of 
both proteins involved in fork protection. Our finding of Olaparib and cisplatin resistance of cells that 
express mutants which are specifically deleterious for fork protection are consistent with the 
resistances of murine cells bearing BARD1-BRCT mutations, which are deficient in nascent strand 
protection due to poor recruitment of the heterodimer to stalled forks49. While our findings build on 
the view that greater RAD51 interactions promote fork protection, further investigation is required 
to explain how the increased RAD51 interaction with BRCA1-BARD1 specifically contributes to the 
function of RAD51 in fork protection. Our current ability to interrogate fork protection remains 
crude and measures observations seen after prolonged fork stalling which are unlikely to be 
physiologically directly relevant. Therefore, we require a greater understanding of fork protection 
mechanisms in order to accurately assess the relationship with therapeutic resistance/sensitivities.  
Mice bearing Bard1-BRCT alleles that confer a fork protection defect are not tumour prone49, and 
restoration of fork protection in a Brca2 knock-out cancer model accelerates, rather than slows, 
tumour formation50. Moreover HR, and not stalled fork protection, is associated with promoting 
human mammary cell viability14. Thus the balance of current evidence does not favour fork 
protection as a tumour suppression mechanism. Nevertheless here we report seven patient-derived 
variants in BRCA1-BARD1 that impair fork protection, four of which appear to have little impact on 
features of HR repair. These data provide a framework to address whether and how BRCA1-
mediated fork protection relates to cancer development.  
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Figure 1. pS114-BRCA1 is required for fork protection 
a-b, IdU/CldU ratios from U20S cells depleted for BRCA1, complemented with Flag-EGFP-BRCA1 
variants and treated with HU (5 mM, 3 hours). n=205 fibres from 2 biological repeats, 
bars=median±95% Confidence Interval (CI). Representative western blot (n=3, b). 
c, Detection of pS114-BRCA1 (rabbit polyclonal) in Flag-IPs from HEK293 cells expressing Flag-EGFP-
WT-BRCA1 or Flag-EGFP-S114A-BRCA1 (representative blot n=3). 
d, Representative Flag-IP from U20S cells expressing RFP-Flag-BARD1 (n=3).  
e, Representative image of GST-PIN1-WW pull down assay from U20S cells expressing Flag-EGFP-WT-
BRCA1 or Flag-EGFP-S114A-BRCA1. GST-W34A-WW-domain was used as a negative control. (n=4, 
data=mean±SEM) 
f, Quantification of enrichment in GST-WW-domain pull downs from HEK293 cell lysates expressing 
Flag-EGFP-WT-BRCA1 treated ±HU (3 mM, 6 hours). (n=4, data=mean±SEM). 
g, pS114-BRCA1 (rabbit polyclonal) was measured following Flag-IP of Flag-EGFP-BRCA1 from 
HEK293 cells treated with 5 μM CDK1/2 inhibitor RO-3306 (representative blot n=3).  
h-i, Representative images (h) and quantification (i) of Proximity Ligation Assay (PLA) between 
pS114-BRCA1 (rabbit polyclonal) and EdU-Biotin in U20S cells at ongoing (-HU) or stalled forks (+HU) 
pulse-labelled with EdU. Scale bars=10µm (i) Includes data from cells depleted for BRCA1 or treated 
with Calf Intestinal Phosphatase (CIP) or Roscovitine (25 µM). n=150 cells from 3 biological repeats. 
Bars=median±95% CI.  
All P-values derived from two-sided unpaired t-test. For gel source data in this figure and throughout 
see Supplementary Figure 1.  
 
Figure 2. PIN1 regulates BRCA1-BARD1 in fork protection 
a-b, IdU/CldU ratios from U20S cells depleted for BRCA1 and/or PIN1 and treated with 5 mM HU, 3 
hours (n=300 fibres from 3 biological repeats, bars=median±95% CI). Representative western blot 
(n=3, b). 
c, Schematic to illustrate cis-trans isomerisation around the BRCA1 phospho-S114 site.  
d-e, IdU/CldU ratios from U20S cells depleted for BRCA1, complemented with Flag-EGFP-BRCA1 
variants and treated with 5 mM HU, 3 hours (n=320 fibres from 3 biological repeats, 
bars=median±95% CI). Representative western blot (n=3, e). 
f-g, As for d, but in cells co-depleted for BRCA1 and PIN1 (n=195 fibres from 2 biological repeats, 
bars=median±95% CI). Representative western blot (n=2, g).  
All P-values derived from two-sided unpaired t-test. n.s =not significant. 
 
Figure 3. BRCA1 isomerisation enhances RAD51 binding 
a, WT and CDK1-phosphorylated-His-BRCA11-300 and His-BARD126-142 incubated with full length GST-
PIN1 to induce isomerisation or catalytically dead GST-PIN1-C113S as a control. Phospho-His-BRCA1-
BARD1 complexes were incubated with recombinant active RAD51 and RAD51-binding was assessed 
by His-purification. Representative image n=3.  
b, Recombinant WT or P115A His-BRCA11-500 and BARD127-327 were incubated with recombinant 
active RAD51 followed by His-purification to assess formation of the BRCA1-BARD1-RAD51 complex. 
Representative image n=5. 
c-d, Percentage of remaining intact BRCA1 (c) or BARD1 (d) protein plotted against incubation time 
from trypsin digests of recombinant full length WT-BRCA1-BARD1 and P115A-BRCA1-BARD1 
(Representative gel shown in Extended Data Fig 6h). Data=mean±SEM, n=3. kp = rate constant of 
proteolysis ± SD.  
e-f, RAD51-EdU PLA foci were measured in U20S cells depleted for BRCA1 (e) or BRCA1 and PIN1 (f), 
complemented with Flag-EGFP-BRCA1 variants and treated with 5 mM HU, 4 hours. 
Data=mean±SEM, n=3.  
All P-values derived from two-sided unpaired t-test. n.s =not significant. 
 
Figure 4. Loss of BRCA1-isomerisation leads to genome instability  
a-c, Colony survival following HU-treatment (16 hours, n-shown in brackets, a) or (5mM, 3 hours, 
n=3, c) was measured in HeLa cells depleted for BRCA1 and complemented with Flag-EGFP-BRCA1 
variants. Data=mean±SEM. Representative western blot (n=3, b). 
d-f, Metaphase spreads from U20S cells depleted for BRCA1, complemented with Flag-EGFP-BRCA1 
variants and treated with HU (5mM, 4 hours). Representative images (d). Red arrows indicate 
chromosome and chromatid breaks. Blue asterisks mark radials. Quantification of chromosome or 
chromatid breaks per metaphase (n=80 metaphases from 4 biological repeats. Data=mean±SEM, e) 
and percentage of metaphases showing 1 or more radial chromosomes. Data=mean±SEM, n=4 (f)  
All P-values derived from two-sided unpaired t-test.   
 
Figure 5. Constitutively expressed P115A-BRCA1 is genotoxic 
a, Accumulation of γH2AX damage foci in EdU-positive U20S cells constitutively expressing Flag-
EGFP-WT-BRCA1 or Flag-EGFP-P115A-BRCA1 over time. n=90 cells from 3 biological repeats. 
Bars=mean±SEM.  
b-d, Metaphase spreads from U20S cells constitutively expressing Flag-EGFP-WT-BRCA1 or Flag-
EGFP-P115A-BRCA1 for 28-36 days. Representative images from day 36 (b). Chromosome breaks 
marked by red arrows. Quantification of metaphase breaks n=80 metaphases from 3 biological 
repeats. Bars=mean±SEM (c). Representative western blot (n=3, d). 
All P-values derived from two-sided unpaired t-test. n.s =not significant. 
 
 
Figure 6. Loss of fork protection in BRCA1-BARD1 patient variants  
a-b, Schematics showing BRCA1 (a) and BARD1 (b) marking the BRCA1-S114-P115 phosphorylation-
isomerisation site, the BARD1-RAD51 binding domain and proximal patient variants with a class-65 
Grantham score.  
c-f, IdU/CldU ratios were measured from U20S cells depleted for BRCA1 (c) or BARD1 (d) and 
complemented with Flag-EGFP-BRCA1 (c) or RFP-Flag-BARD1 (d) variants and treated with HU (5 
mM, 3 hours). n=300 fibres (BRCA1); n=275 fibres (BARD1) both from 3 biological repeats, 
bars=median±95% CI. Representative western blot for BRCA1 (n=3, e) and BARD1 (n=3, f) variants. 
g-i, Colony survival following HU-treatment (16 hours) was measured in HeLa (g) or U20S cells (h-i) 
depleted for BRCA1 (g-h) or BARD1 (i) and complemented with Flag-EGFP-BRCA1 (g-h) or RFP-Flag-
BARD1 (i) variants. Data=mean±SEM. n-values given in brackets for each condition. 
All P-values derived from two-sided unpaired t-test. 
 
  
Methods (online only) 
Site-Directed Mutagenesis. Specific primers were designed for mutagenesis (Supplementary Table 
1) and mutagenesis performed by PCR using PfU (Promega). All mutagenesis was confirmed by 
Sanger Sequencing (Source Bioscience).  
Tissue culture. Parental Flp-InTM HeLa, U20S and HEK293 cells were obtained from Morris Lab cells 
stocks and grown in Dulbeccos Modified Eagle Media (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% Penicillin/Streptomycin. Cells were cultured in Corning T75 flasks and 10 cm2 
plates and kept at 5% CO2 and 37 °C. Once cells reached 70-80% confluency they were passaged. 
Cells were tested for Mycoplasma by Hoescht staining. Cell lines have not been authenticated. 
Inducible stable cell line generation. Stable cell lines were generated from Flp-InTM HeLa, U20S and 
HEK293 cells cells co-transfected with the gene of interest cDNA in the pcDNA5/FRT/TO vector and 
the Flp recombinase cDNA in the pOG44 vector. Control transfections were carried out without the 
pOG44 recombinase. Two days after transfection, cells were selected with 100 μg/ml Hygromycin, 
cell culture medium was replaced every 2-3 days and cells were selected for approximately 2 weeks. 
After selection cells were expanded and tested for expression of Flag-EGFP-BRCA1, RFP-Flag-BARD1 
or Flag-PALB2. Cells were treated with 2 μg/ml Doxycycline for 24, 48 and 72 hours and expression 
levels were checked by western blotting. 
Plasmid and siRNA transfection. FuGENE 6 (Roche) was used as a reagent to transfect DNA plasmids 
into cells, the ratio used was 4:1 FuGENE (μl): DNA (μg), following the manufacturer’s guidelines. 
siRNA transfections were carried out using the transfection reagent Dharmafect1 (Dharmacon) 
following the manufacturer’s instructions. For a full list of siRNA sequences see Supplementary Table 
2. 
Colony survival assays. Flp-InTM U20S or HeLa cells were plated in 24 well plates at 4 x 104 cells/ml 
and treated according to the experiment performed. Cells were trypsinised in 100 μl of 1x Trypsin 
and resuspended in 900 μl of PBS. Cells were plated out at limiting dilutions and incubated for a 
further 10-14 days at 37 °C at 5 % CO2. Once colonies had grown they were stained with 0.5 % 
Crystal violet in 50 % methanol and counted. For a full list of DNA damaging agents and inhibitors, 
see Supplementary Table 3.  
GST-PIN1-WW Pull down assay. Cells were washed with 10 ml ice cold PBS before being lysed in 5 
ml TG lysis buffer (40 mM Tris-HCL pH 8, 274 mM NaCl, 2 mM EGTA, 3 mM MgCl2, 2 % Triton x100, 
20 % Glycerol) with addition of cOmplete protease inhibitor cocktail (Roche) and PhosSTOP (Roche) 
tablets. The lysed cells were transferred into 1.5 ml Eppendorf tubes incubated on ice for 20 mins 
and sonicated twice at 20 % intensity for 10 seconds. Samples were spun at 13000 rpm at 4 °C for 10 
mins and the supernatant kept. 50 μl of the supernatant was mixed with 20 μl 4x SDS Loading buffer 
and boiled at 95 °C for 5 mins. 800 μl of the cell supernatant was then incubated with equal 
concentrations of GST-WW PIN1 and GST-W34A PIN1 beads for 2 hours at 4°C. The GST-pull downs 
were washed three times in TG lysis buffer before adding 60 μl 4x SDS loading buffer directly to the 
beads. Samples were boiled at 95 °C for 5 mins and then 40 μl loaded onto an SDS PAGE gel and 
analyzed by western blotting.  
Flag immunoprecipitation. Stable U20S or 293 cells were plated in a 10 cm2 plate and treated with 
Doxycycline for 48 hours to express inducible Flag-EGFP-BRCA1 or RFP-Flag-BARD1 or 293 cells were 
transiently transfected with 4 µg pcDNA5/FRT/TO-Flag-EGFP-BRCA1 and/or pcDNA5/FRT/TO-RFP-
Flag-BARD1 for 48-72 hours. Cells were washed with 10 ml ice cold PBS before being scraped in ice 
cold Nuclear Lysis Buffer (10 mM HEPES pH7.6, 200 mM NaCl, 1.5 mM MgCl2, 10 % Glycerol, 0.2 mM 
EDTA, 1 % Triton) with addition of cOmplete protease inhibitor cocktail (Roche) and PhosSTOP 
(Roche) tablets, 1 U/ml DNAse1 (Thermofisher) and 20 μM MG132 for every 10 ml. The lysed cells 
were then transferred into 1.5 ml Eppendorf tubes incubated on ice for 30 mins. Samples were spun 
at 13000 rpm at 4°C for 10 mins and the supernatant kept, the pellet was discarded. 50 μl of the 
supernatant was mixed with 20 μl 4x SDS Loading buffer and boiled at 95°C for 5 mins. For every IP, 
10 μl Flag-agarose beads were firstly washed out of storage buffer by doing 3x 1ml PBS washes and 
centrifuging at 3000 rpm between each wash. 90 μl of PBS was added for every 10 μl of agarose 
beads. Once the beads were resuspended in PBS, 100 μl were transferred into an Eppendorf with 
500 μl of supernatant and 500 μl of PBS. The Eppendorfs were rotated for 2 hours at 4°C. Samples 
were centrifuged at 3000 rpm for 1 min and the beads left to settle. The supernatant was then 
removed before 3x 1 ml PBS-0.02% tween washes. The wash buffer was completely removed before 
adding 60 μl 2x SDS loading buffer. This was boiled at 95°C for 5 mins and then 30 μl loaded onto an 
SDS PAGE gel and analysed by western blotting.  
Western blotting. For a full list of antibodies see Supplementary Table 4. Samples were fun on 
acrylamide SDS PAGE protein gels and transferred to PVDF Immobilon-P membrane. Following 
transfer membranes were blocked in 5 % marvel milk in PBS with 0.1 % Tween (PBStw) or in 5 % BSA 
with PBStw, for a minimum of 1 hour before incubation with primary antibody at 4 °C for 16 hours. 
Blots were washed 3x 10 mins in PBStw and then transferred into secondary HRP antibodies in 5 % 
marvel milk for a minimum of 1 hour. Blots were again washed 3x 10 mins in PBStw before probing 
with 1:1 EZ-ECL mix (Biological Industries). Blots were exposed to X-Ray film (Wollf Labs) and 
developed using the Xograph Compact X4 developer. Densitometry calculations were performed 
using Image J. Source data for uncropped gel images for western blots are available in 
Supplementary Figure 1. 
p-S114 Antibody Generation. Custom mouse monoclonal (3C10G8) and rabbit polyclonal antibodies 
were raised against BRCA1 phospho-S114 by Genscript using the following peptide: 
CFAKKENNpSPEHLKD. These antibodies are available on request to the corresponding authors 
subject to completion of a standard MTA. 
Fibre labelling and spreading. Cells were seeded in 6 cm2 plates at a density of 20x 104 cells/well and 
treated with thymidine analogues CldU and IdU. To monitor stability of nascent DNA, cells were 
incubated at 37 °C with CldU for 20 mins at a final concentration of 25 μM, followed by incubation 
with IdU (250 µM) for 20 mins and then with 5 mM HU for 3 hours. To monitor CldU fibre lengths, 
cells were incubated at 37 °C with CldU for 20 mins at a final concentration of 25 μM and then with 5 
mM HU for 3 hours. To monitor replication fork restart, cells were incubated at 37 °C with CldU for 
20 mins at a final concentration of 25 μM and then with 5 mM HU for 3 hours. The HU was then 
washed out with 3x PBS washes and cells were incubated for a further 40 mins in media containing 
250 μM IdU at 37°C.  
After incubation with thymidine analogues, cells were washed 2x with ice-cold PBS for 5 minutes 
with rotation then trypsinised, resuspended in 1ml of PBS and counted. The optimal concentration is 
50 x 104 cells/ml and thus cells were adjusted to such concentration. 2 μl of the cell sample was 
placed on Snowcoat microscope slides and allowed to slightly dry for 7 mins. Then 7 μl of spreading 
buffer (200 mM Tris pH7.4, 50 mM EDTA, 0.5% SDS) was mixed with the sample and incubated for 2 
mins to lyse the cells. In order to spread the sample down the slide, slides were gradually tilted and 
once the sample had reached the bottom of the slide, they were allowed to dry for 2 mins. Finally, 
slides were fixed in a 3:1 ratio of Methanol: Acetic acid for 10 mins before leaving slides to air dry for 
5-10 mins. Dried slides were stored at 4°C till staining. 
Fibre Immunostaining. After fibre spreading slides were washed twice for 5 minutes with 1 ml H2O 
and rinsed with 2.5 M HCl before denaturing DNA with 2.5 M HCl for 1 hour 15 mins. Slides were 
then rinsed 2 x with PBS and washed for 5 minutes in blocking solution (PBS, 1 % BSA, 0.1 % 
Tween20). Slides were incubated for 1 hour in blocking solution. After blocking, each slide was 
incubated with 115 μl of primary antibodies, Rat αBrdU (AbD Serotec/Abcam) to detect CldU used at 
a concentration of 1:2000 and Mouse αBrdU (Becton Dickinson) to detect IdU used at 1:750. Slides 
were covered with large coverslips and incubated with the antibodies for 1 hour. After incubation 
with the primary antibody, slides were rinsed 3x with PBS and then incubated for 1 min, 5 mins and 
30 mins, with blocking solution. After rinsing and washing, slides were incubated with 115μl of 
secondary antibodies (α-Rat AlexaFluor 555 and α-Mouse AlexaFluor 488) in blocking solution, at a 
concentration of 1:500, covered with a large coverslip for 2 hours. Slides were rinsed 3x with PBS 
and incubated with blocking solution for 1 min, 5 mins and 30 mins. After again rinsing 2 x with PBS, 
immunomount mounting media was added to the slide and a large coverslip placed over and left to 
dry. Coverslips were then stored at -20°C for microscopy analysis. It is important to point out that 
during this process slides must be kept protected from light. 
Following imaging using a Leica DM6000B fluorescence microscope, CldU and IdU fibre lengths were 
measured for ongoing forks containing both labels using Image J. The ratio of IdU/CldU was 
determined for each ongoing fork for a minimum of 100 fibres per experiment and each experiment 
was repeated 3 times.  
Fork restart was measured as the percentage of fibres with incorporation of both labels (CldU & 
IdU). Stalled forks were fibres with only first label (CldU). Percentage was calculated accordingly to 
the total number of fibres counted.  
Immunofluorescent staining. U20S WT or S114A-BRCA1 cells were plated at a density of 5 x 104 
cells/ml in 24 well plates on circular glass coverslips (13 mm). Cells were treated siBRCA1 for 48 
hours and complemented with WT or S114A BRCA1 by addition of Doxycycline. Cells were then 
treated with 20 µM Olaparib for 2 hours. Cells were pre-permeablised by incubation with CSK buffer 
(100 mM sodium chloride, 300 mM sucrose, 3 magnesium chloride, 10 mM PIPES pH 6.8) on 
ice for 1 minute before fixation with 4 % PFA. Once fixed the cells were permeabilised for a further 5 
mins using 0.5 % TritonX in PBS before incubation with blocking solution - 10% FCS in PBS for 30 
mins. Cells were then incubated with rabbit polyclonal RAD51 (H92) antibody in 10% FCS PBS at 
room temperature overnight. The following day, cells were washed in PBS/FCS before incubating 
them with AlexaFluor-488 secondary antibody at a 1:2000 concentration, for 2 hours. Cells were 
then washed three times in PBS and the DNA stained using Hoescht at a 1:20000 concentration for 5 
mins. Excess of Hoescht was washed with PBS and coverslips mounted onto Snowcoat slides using 
Immunomount mounting media. 
EdU staining. Cells subjected to immunofluorescent staining were also subjected to EdU staining. 
Cells were incubated with 10 μM final concentration of EdU for 2 hours prior to fixing and staining 
was carried out as detailed in the Click-iT® EdU Imaging Kits (Life Technologies). 
CldU Immunostaining.  Cells were plated at a density of 5 x 104 cells/ml in 24 well plates on circular 
glass coverslips (13 mm). Cells were treated as described and incubated at 37 °C with CldU for 20 
mins at a final concentration of 25 μM. Cells were then fixed with 4 % PFA and permeabilised for 5 
mins using 0.25 % TritonX in PBS. After permeabilisation, cells were washed twice with PBS and 
twice with blocking solution containing 10 % FCS in PBS. 2 M HCl was added for 30 mins at 37 °C and 
cells incubated with 10 % FCS in PBS for 1 hour at room temperature (RT). Cells were then incubated 
with anti-Flag (M2-Sigma)(1:1000) and Rat αBrdU (AbD Serotec) (1:500), in 10 % FCS PBS at RT, for 1 
hour. After primary antibody incubation, cells were washed 3x in PBS and then incubated for 10 mins 
in stringency buffer (0.5 M NaCl, 36 mM Tris pH 7.5-8, 0.5 % Tween20), before incubating them with 
AlexaFluor antbodies at a 1:500 concentration, for 2 hours. Cells were then washed twice with PBS 
and once with stringency buffer, and DNA stained using Hoescht at a 1:20000 concentration for 5 
mins. Excess of Hoescht was washed with PBS and coverslips mounted onto Snowcoat slides using 
Immunomount mounting media. 
Proximity Ligation Assay. Flp-InTM U20S cells were seeded at 4 x 104 cells/ ml onto poly-L-lysine 
coated coverslips and EdU pulsed for 10 minutes at 37°C for 10 minutes. 5 mM HU was then added 
into media for 4 hours at 37 °C. Likewise, cells were treated with Roscovitine (25 µM) for 4 hours at 
37 oC. Cells were pre-extracted for 5 minutes on ice with Pre-extraction buffer (20 mM NaCl, 3 mM 
MgCl2, 300 mM Sucrose, 10 mM PIPES, 0.5 % Triton X-100) and fixed in 4 % PFA for 10 minutes 
before blocking in 10 % BSA for 16 hours. Blocking media was removed and click it reaction cocktail 
(PBS, 10 μM Biotin Azide, 10 mM sodium ascorbate, 1 mM CuSO4) was added for 1 hour at room 
temperature. Click it reaction was washed and cells blocked in 10 % BSA for 30 minutes. Cells were 
then incubated with primary antibodies, Biotin (Jackson Immunoresearch) and RAD51 (Calbiochem) 
or pS114-BRCA1 (rabbit polyclonal) in 5 % FCS in PBS for 1 hour at room temperature. After 
incubation with primary antibodies cells were incubated with the MINUS/PLUS PLA probes (Sigma 
Duolink PLA kit) for 1 hour at 37 °C in a warm foil covered box. Cells were then washed twice for 5 
minutes with wash buffer A (Sigma Duolink PLA kit) and incubated with the Sigma Duolink Ligation 
kit (1X ligation buffer, ligase enzyme) for 30 minutes at 37 °C. Cells were washed twice for 5 minutes 
with wash buffer A and incubated for 100 minutes at 37 °C with the Sigma Duolink amplification kit 
(1X amplification buffer, polymerase enzyme). Finally they were washed twice for 10 minutes with 
wash buffer B (Sigma Duolink PLA kit) at room temperature and coverslips were mounted using the 
Duolink mounting media with DAPI (Sigma). For cells treated with Calf Intestinal Phosphatase (CIP) 
(NEB), fixed cells were re-permeabilised with 0.2 % TritonX100 in PBS for 5 minutes before 
incubation with 20 U of CIP for 20 minutes at 4 oC. Cells were then blocked and assayed as described 
above.   
Microscopy. Immunofluorescent staining was imaged using the Leica DM6000B microscope using a 
HBO lamp with 100W mercury short arc UV bulb light source and four filter cubes, A4, L5, N3 and Y5, 
which produce excitations at wavelengths 360 488, 555 and 647 nm respectively. 
Metaphase spreads. Flp-InTM U20S cells were treated with 5 mM HU for 4 hours and then incubated 
with Colcemid (0.05 µg/ml) 16 hours. Cells were trypsinized and centrifuged at 1200 rpm for 5 
minutes. Supernatant was discarded and cells resuspended in PBS. 5 ml of ice-cold 0.56 % KCl 
solution was added and incubated at room temperature for 15 min before centrifuging at 1200 rpm 
for 5 min. Supernatant was discarded and cell pellet broken before fixation. Cells were then fixed in 
5 ml of ice-cold methanol: glacial acetic acid (3:1). Fixation agents were removed and 10 μl of cell 
suspension was dropped onto an acetic acid humidified slide. Slides were allowed to dry for at least 
24 hours and then stained with Giemsa solution (Sigma) diluted 1:20 for 20 min. Slide mounting was 
performed with Eukitt (Sigma).  
Protein expression and purification 
WT and P115A His-BRCA11-500 -BARD127-327 for in vitro analysis The expression of His-BRCA1-WT + 
BARD1-WT and His-BRCA1-PA + BARD1-WT in Rosetta™(DE3) was induced by the addition of 1 mM 
Isopropyl-β-d-thiogalactopyranoside (IPTG), and the proteins were produced in LB medium 
containing 50 μg/ml of kanamycin, 100 μg/ml of ampicillin and 30 μg/ml of chloramphenicol at 37°C 
for 5 hours. For purification of the His-BRCA1-WT + BARD1-WT and His-BRCA1-PA + BARD1-WT 
products, the cells were harvested and resuspended in 20 mM HEPES potassium salt, pH 7.4, 50 mM 
Imidazole, 500 mM NaCl, 1.0 mM TCEP [tris(2-carboxyethyl)phosphine], cOmplete EDTA-free 
protease inhibitor cocktail tablet (Roche). Cells were lysed using an Emulsiflex-C3 homogenizer 
(Avestin) and broken by three passages through the chilled cell. The lysate was centrifuged at 75,000 
xg using a JA 25.50 rotor (Beckman Coulter) and filtered through a 0.45-μm filter. The clarified lysate 
was applied onto a 5-ml HisTrap HP column (GE Healthcare). The column was washed extensively 
using the same buffer, and the protein was eluted using buffer containing 500 mM imidazole. 
Fractions containing a band of the correct size were concentrated using a Vivaspin 20-ml 
concentrator (10,000 molecular weight cut-off [MWCO]) (GE Healthcare) and gel purified using an 
Akta Pure 25 (GE Healthcare LS) with a prepacked Hi-Load 10/300 Superdex 200 PG column. 
WT and S114A BRCA11-300 -HisBARD126-142  for CDK kinase assay. BRCA1 and BARD1 proteins were 
expressed from pET15b-His-BRCA11-300:His-BARD126-142 vector in BL21(DE3) bacteria (Bioline). 
Bacteria were grown at 37 °C until an optical density of 0.6 was reached. Protein expression was 
induced by addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) (Bioline), and the 
temperature was immediately decreased to 25 °C. Bacteria were grown for a further 24 h. Bacterial 
pellets were collected after centrifugation at 3,000g for 10 min at 4 °C and then lysed in ice-cold lysis 
buffer (50 mM sodium phosphate, pH 7, 300 mM sodium chloride, 5% glycerol and 10 mM β-
mercaptoethanol). Lysates were sonicated for 1 min at 30 % intensity and then clarified by 
centrifugation at 14000g for 10 min at 4 °C. The supernatant was incubated with 0.25 ml His-select 
beads (Sigma) overnight at 4 °C with rotation. The following day, the beads were washed three times 
with ice-cold wash buffer (50 mM sodium phosphate, pH 7, 300 mM sodium chloride, 5 % glycerol, 
10 mM β-mercaptoethanol and 50 mM imidazole) before elution on ice in 50 mM sodium 
phosphate, pH 7, 300 mM sodium chloride, 5 % glycerol, 10 mM β-mercaptoethanol and 300 mM 
imidazole. Purified proteins were dialyzed against (25 mM Tris-HCl, pH 7.5, 10 % glycerol, 2 mM 
dithiothreitol (DTT) and 150 mM potassium chloride), and purity was assessed by resolution on a 15 
% SDS–PAGE gel. 
 
GST-PIN1 and GST-PIN1-WW purification. Bl21 Escherichia Coli were transformed with the pGEX 
protein expression vector containing either full length PIN1 or the WW domain of PIN1 (WT or 
W34A). Colonies were picked and grown up in 50 ml starter cultures containing Ampicillin at 37°C for 
16 hours at 200 rpm. Starter cultures were transferred to 500 ml Luria Bertani (LB) containing Amp 
and grown for 2 hours at 37 °C at 200 rpm. Bacterial expression was induced using 0.5 mM IPTG and 
bacteria left to grow for 5 hours at 37°C at 200 rpm. 
Bacteria were pelleted by centrifuging at 12000 rpm for 10 mins at 4°C. Then the bacterial pellet was 
lysed in 10 ml GST lysis buffer (20 mM Tris-HCL pH8, 130 mM NaCl, 1 mM EGTA, 1.5 mM MgCl2, 1 % 
Tritonx-100, 10 % Glycerol, 1 mM DTT) with 1 protease inhibitor tablet (Roche). Bacteria were 
resuspended and left on ice for 20 mins and then sonicated 2 times at 20% intensity for 10 seconds. 
Lysed bacteria were spun 20 mins at 13000 rpm to pellet debris. Supernatant was transferred to a 50 
ml falcon tube and made up to 35 ml with lysis buffer and 500 μl of pre-washed Glutathione 
Sepharose 4B beads (GE Life Sciences) and rotated at 4°C for 16 hours.  
CDK Kinase assays. 50 ng of WT or S114A His-BRCA11-300:His-BARD126-142 were incubated with 50ng 
of recombinant CDK1-Cyclin A2 (Thermofisher PV6280), CDK2-Cyclin A (Thermofisher PV3267) or 
CDK9/Cyclin K (Thermofisher PV4335) in 25 mM MOPS pH7.2, 12.5 mM β-glycerolphosphosphate, 25 
mM magnesium chloride, 5mM EGTA, 2 mM EDTA, 0.5 mM DTT and 50 ng/µl BSA. The kinase 
reaction was started by addition of 10 mM ATP and samples were incubated at 30 oC for 30 minutes. 
The reaction was stopped by addition of 4x SDS-PAGE loading buffer and incubated at 95 oC for 5 
minutes. 5 µl of the total reaction was run on 14 % SDS PAGE gel before transfer to Immobilon-P 
membrane (MERCK-Millipore) and western blotting for phospho-S114 (3C10G8) or BRCA1 (MS110). 
RAD51 in vitro binding assay (BRCA1-BARD1 N-terminal fragments) 0.5 μl of Human recombinant 
RAD51 (ab63808 - Abcam) was incubated with 40 μl of a 50% slurry of His-BRCA1-WT + BARD1-WT 
or His-BRCA1-PA + BARD1-WT immobilized in Ni2+-resin together with 500 μl of RAD51 binding buffer 
(25 mM Tris-HCl pH 7.5, 10% Glycerol, 0.5 mM EDTA, 0.05% Igepal CA-630, 1mM 2-mercaptoethanol, 
150 mM KCl, 50mM Imidazole) for 30 minutes at 4°C in rotation. After incubation the resin was 
washed three times with the RAD51 binding buffer before eluting in 40 μl 4x SDS loading buffer at 
95°C for 5 minutes. The SDS elute was then analyzed by Western blotting and Coomassie blue 
staining.  
In vitro PIN1 incubations with BRCA1-BARD1 and RAD51 Using recombinant BRCA1 preps 50 µl of 
HisBRCA11-500-BARD127-327 WT or the phosphomimic S114D was incubated at 37 oC for 1 hour with 2 
ul of full length GST-PIN1 or BSA in 10 mM ATP in 50 mM Tris pH7.4, 500mM NaCl, 1 mM DTT, 500 
mM Imidazole, 5 % glycerol and 0.01% Igepal CA630. This was then incubated for a further 2 hours at 
4 oC with 0.5 μl of Human recombinant RAD51 (ab63808 - Abcam) in 500 µl of RAD51 binding buffer 
(25 mM Tris-HCl pH 7.5, 10% Glycerol, 0.5 mM EDTA, 0.05% Igepal CA-630, 1mM 2-mercaptoethanol, 
150 mM KCl, 50mM Imidazole) and 30 µl of His-Select beads (Sigma). Beads were then washed 3-
times in RAD51 binding buffer before eluting in 60 μl 4x SDS loading buffer at 95°C for 5 minutes. 
Alternatively, 0.3 µg of WT HisBRCA11-300-HisBARD126-142 was incubated with or without 100 ng of 
recombinant CDK1-Cyclin A2 (Thermofisher PV6280), in 150 µl of 25 mM MOPS pH7.2, 12.5 mM β-
glycerolphosphosphate, 25 mM magnesium chloride, 5mM EGTA, 2 mM EDTA, 0.5 mM DTT and 50 
ng/µl BSA with 20 mM ATP at 37 oC for 2 hours. Subsequently, 50 µl BSA, or WT HisBRCA11-300-
HisBARD126-142 or CDK1-phosphorylated HisBRCA11-300-HisBARD126-142 was incubated with 2 ul of full 
length GST-PIN1 or BSA in 10 mM ATP in 50 mM Tris pH7.4, 500mM NaCl, 1 mM DTT, 500 mM 
Imidazole, 5 % glycerol and 0.01% Igepal CA630 for 5 minutes at room temperature. This was then 
incubated for a further 2 hours at 4 oC with 0.5 μl of Human recombinant RAD51 (ab63808 - Abcam) 
in 500 µl of RAD51 binding buffer (25 mM Tris-HCl pH 7.5, 10% Glycerol, 0.5 mM EDTA, 0.05% Igepal 
CA-630, 1mM 2-mercaptoethanol, 150 mM KCl, 50mM Imidazole) and 30 µl of His-Select beads 
(Sigma). Beads were then washed 3-times in ice cold PBS before eluting in 60 μl 4x SDS loading 
buffer at 95°C for 5 minutes. 
Full length BRCA1-BARD1 cloning and purification. His-BRCA1-Strep and BARD1 genes were 
synthesised with codons optimised for insect cell expression. Mutagenesis was carried out by 
PCR using CloneAmp HiFi PCR premix (Takara) and the primers indicated in Supplementary Table 
1. Mutagenesis was confirmed by Sanger sequencing (Eurofins). Genes were cloned into the 
MultiBac system for expression in insect cells 51. 
BRCA1-BARD1 complexes were expressed in Sf9 insect cells for 60 hours post-infection in Insect-
XPRESS Protein-free Insect Cell Medium with L-Glutamine (Lonza). Cells were harvested 
and resuspended in lysis buffer (50 mM NaPO4, pH 8.0, 150 mM KCl, 0.5% NP-40, 0.01% Tween-20, 
10% glycerol, 0.5 mM TCEP), BaseMuncher (Expedeon, UK), 1 mM benzamidine, and protease 
inhibitors (AEBSF 1 mM, aprotinin 800 nM, bestatin 50 μM, E-64 15 μM, leupeptin 
20 μM, pepstatin 10 μM). The lysate was clarified by centrifugation at 36,000 x g for 1 hour at 4°C, 
passed through a 0.45 μm syringe filter and loaded onto a 5 mL StrepTrap HP column (GE 
Healthcare, USA). The column was washed with lysis buffer followed buffer A (50 mM NaPO4, pH 
8.0, 150 mM KCl, 0.01% Tween-20, 10% glycerol, 0.5 mM TCEP) and then buffer B (50 mM NaPO4, 
pH 8.0, 50 mM KCl, 0.01% Tween-20, 10% glycerol, 0.5 mM TCEP). The protein was eluted onto a 1 
mL HiTrap SP HP column (GE Healthcare) using elution buffer (wash buffer B supplemented with 0.4 
mg/ml d-Desthiobiotin (Sigma, USA)). The SP column was washed with buffer C (25 mM HEPES, pH 
7.4, 0.01% Tween-20, 10% glycerol, 0.5 mM TCEP) supplemented with 50 mM KCl. The protein was 
then eluted using a 0.05 – 1 M KCl gradient in buffer C. Peak fractions were pooled and concentrated 
with an Amicon 100 kDa MWCO centrifugal filter unit (Sigma). The concentrated protein was loaded 
onto a Superose 6 Increase 10/300 column (GE Healthcare) and gel filtrated in buffer C 
supplemented with 150 mM KCl. Peak fractions were pooled, flash frozen in liquid nitrogen, and 
stored at -80°C.   
 
RAD51 purification (for binding assays to full length BRCA1-BARD1). RAD51 was purified according 
to the protocol described by Subramanyam 52. Briefly, RAD51 was expressed from Acella DE3 E. coli 
induced with IPTG for 4 hours at 37°C. The pellet was resuspended in lysis buffer (100 mM Tris-OAc, 
pH 7.5, 2 mM EDTA, 10% glycerol, 1 mM DTT, protease inhibitor cocktail, lysozyme 0.5 mg/mL, 0.1% 
Triton X-100). The resuspended cells were sonicated and the lysate clarified by centrifugation at 
18,000 rpm at 4°C for 1 hr 20 min. The supernatant was dialysed in spermidine acetate buffer (20 
mM Tris-OAc pH 7.5, 7 mM spermidine, 5% glycerol, 0.1 mM DTT). RAD51 was selectively 
resuspended in buffers containing an increasing concentration of NaCl. The fractions were then 
purified with a HiTrap Q HP column (GE Healthcare).  
RAD51 in vitro binding assays (full length BRCA1-BARD1)  
BRCA1-BARD1 (0.5 μM) was pre-incubated with RAD51 (5 μM, gifted by Yueru Sun) for 30 min at 4°C. 
80 μL of a 50% slurry of Streptactin Sepharose High Performance Resin (GE Healthcare) in binding 
buffer (25 mM Tris-HCl, pH 7.5, 90 mM KCl, 1 mM TCEP, 0.2% Tween-20), with 5mM MgCl2 and 3 
mM ATP, was added and incubated for a further 30 min at 4°C. The resin was washed with 2 mL 
binding buffer and eluted with 40 μL 4x NuPAGE LDS Sample Buffer (ThermoFisher). Samples were 
run on SDS-PAGE and stained with Coomassie blue (Expedeon).  
 
Trypsin proteolytic digestion  0.1 mg/mL of full-length BRCA1-BARD1 was subjected to proteolytic 
digestion with 0.01 ng/µL trypsin (Sigma) in 25 mM Tris-HCl, pH 7.5, 90 mM KCl, 1 mM TCEP, 0.2% 
Tween-20. Samples were incubated at room temperature and 20 µL samples were collected at time 
points 0, 2, 5, 10, 15, 20, 30, 60 min and quenched with 5 µL 4x NuPAGE LDS Sample Buffer 
(ThermoFisher). Samples were boiled at 100°C for 5 mins and 20 µL loaded onto an SDS-PAGE gel. 
Gels were stained with Coomassie blue (Expedeon) and band intensities of full length BRCA1 and 
BARD1 was measured using ImageJ software53. The rate constant of proteolysis (kp) was determined 
by non-linear fitting to an exponential one phase decay curve in GraphPad Prism 8.0.2 software.  
Densitometry. All densitometry was calculated using ImageJ53 to quantify western blot and 
Coomassie-stained band intensities. For GST-PIN1-WW pull downs quantification measured the fold 
change of BRCA1 levels observed in the pull downs normalised to the amount of BRCA1 in the 
corresponding Inputs. All quantification is from at least 3-independent experiments.  
For the densitometry to calculate the levels of RAD51 in the Flag- immunoprecipitation (Extended 
Data Fig 5e-f) we calculated the relative amounts of RAD51, BRCA1 and BARD1 in the Flag-IP from 
293 FlpIn cells using densitometry performed with Image J. The amount of RAD51 enrichment was 
then calculated by normalising RAD51 to the combined levels of BRCA1 and BARD1 for each IP. To 
calculate percentage of intact protein in the trypsin proteolytic digestions, the amount of full-length 
protein was normalised to that at 0 min. 
DR-GFP U2OS-DR3-GFP (gene conversion reporter cell line) were a generous gift from Jeremy Stark 
(City of Hope, Duarte USA). U20S reporter cell lines were simultaneously co-transfected with siRNA 
using Dharmafect1 (Dharmacon) and DNA (RFP, or RFP-Flag-BARD1 and I-Sce1 endonuclease 
expression constructs) using FuGene6 (Promega) respectively. After 16 hr the media was replaced 
and cells were grown for a further 48 hr before fixation in 2% PFA. RFP and GFP double positive cells 
were scored by FACS analysis using a CyAn flow cytometer and a minimum of 10000 cells counted. 
Data was analysed using Summit 6.2 software. Each individual experiment contained 3 technical 
repeats and normalized to siRNA controls or to WT-complemented cells. Graphs shown are 
combined data from 6 independent experiments and error bars show standard error. FACs gating 
strategy is shown in Supplementary Figure 1.  
 
Statistics and Reproducibility. All statistics were done using two-sided unpaired t-test and exact P-
values are given in each case. n.s = not-significant. All experiments were repeated to generate 
biological replicates. The n-value is reported for each experiment.  
 
 
 
 
Supplementary Table 1 - Oligonucleotide primers used for cloning and site-directed mutagenesis 
Gene Cloning & Mutagenesis Primers  Primer Sequence 
BRCA1 Y101N_F GACACAGGTTTGGAGAATGCAAACAGC 
 Y101N_R GCTGTTTGCATTCTCCAAACCTGTGTC 
 S114A_F GGAAAATAACGCTCCTGAACATC 
 S114A_R GATGTTCAGGAGCGTTATTTTCC 
 S114D_F GGAAAATAACGACCCTGAACATC 
 S114D_R GATGTTCAGGGTCGTTATTTTCC 
 S114P_F GGAAAATAACCCTCCTGAACATC 
 S114P_R GATGTTCAGGAGGGTTATTTTCC 
 P115A_F (Flag-EGFP-BRCA1) GGAAAATAACTCTGCTGAACATCTAAAAG 
 P115A_R (Flag-EGFP-BRCA1) CTTTTAGATGTTCAGCAGAGTTATTTTCC 
 P115A_F (recombinant-BRCA1) AAACAACTCAGCTGAGCACCT 
 P115A_R (recombinant-BRCA1) AGGTGCTCAGCTGAGTTGTTT 
 P115C_F GGAAAATAACTCTTGTGAACATCTAAAAG 
 P115C_R CTTTTAGATGTTCACAAGAGTTATTTTCC 
 S114AP115A_F GGAAAATAACGCAGCAGAACATC 
 S114AP115A_R GATGTTCTGCTGCGTTATTTTCC 
 S114AP115C_F GGAAAATAACGCTTGTGAACATCTAAAAG 
 S114AP115C_R CTTTTAGATGTTCACAAGCGTTATTTTCC 
 Y179C_F GACGTCTGTCTGCATTGAATTGGGATC 
 Y179C_R GATCCCAATTCAATGCAGACAGACGTC 
 S184C_F CATTGAATTGGGATGTGATTCTTCTGAAG 
 S184C_R CTTCAGAAGAATCACATCCCAATTCAATG 
 S265Y_F GTATCAGGGTAGTTATGTTTCAAACTTGC 
 S265Y_R GCAAGTTTGAAACATAACTACCCTGATAC 
 M1411T_F CTCCAGCAGGAAACGGCTGAACTAGAAGC 
 M1411T_R GCTTCTAGTTCAGCCGTTTCCTGCTGGAG 
BARD1 AAE_F CCTAGGAAAAGTTTGGCTAATGCTGAAGGAAACAAGAAGAATTC 
 AAE_R GAATTCTTCTTGTTTCCTTCAGCATTAGCCAAACTTTTCCTAGG 
 D135Y_F CAGATTTGAAAGAATATAAACCTAGGAAAAG 
 D135Y_R CTTTTCCTAGGTTTATATTCTTTCAAATCTG 
 K144N_F GAAGAATTCAATTAACATGTGGTTTTCGC 
 K144N_R GCGAAAACCACATGTTAATTGAATTCTTC 
 F147C_F CAATTAAAATGTGGTGTTCGCCACGTAGTAAG 
 F147C_R CTTACTACGTGGCGAACACCACATTTTAATTG 
 S148A_F CAATTAAAATGTGGTTTGCGCCACGTAGTAAG 
 S148A_R CTTACTACGTGGCGCAAACCACATTTTAATTG 
 S148D_F CAATTAAAATGTGGTTTGACCCACGTAGTAAG 
 S148D_R CTTACTACGTGGGTCAAACCACATTTTAATTG 
PALB2 ΔNT-PALB2_F GAAAAGATTAAGCATTCTATTAAGAAAACAG 
 ΔNT-PALB2_R CATGGTGGAGCCTGCTTT 
PIN1 PIN1 WW STOP_F CGGCCCAGCGGCTAAAGCAGCAGTGG 
 PIN1 WW STOP_R CCACTGCTGCTTTAGCCGCTGGGCCG 
 PIN1 W34A_F GCCAGCCAGGCGGAGCGGCCC 
 PIN1 W34A_R GGGCCGCTCCGCCTGGCTGGC 
 PIN1 C113S_F GTTCAGCGACTCCAGCTCAGCC 
 PIN1 C113S_R GGCTGAGCTGGAGTCGCTGAAC 
 
 
  
Supplementary Table 2 - siRNA sequences 
Target siRNA Sequences Supplier 
NTC (Renilla 
Luciferase) 
Sense:  CUUACGCUGAGUACUUCGA[dT][dT] 
Antisense: [Phos]UCGAAGUACUCAGCGUAA G[dT][dT] 
Sigma Aldrich 
BARD1 Sense: UGGUUUAGCCCUCGAAGUAAG[dT][dT] 
Antisense: [Phos]CUUACUUCGAGGGCUAAACCA[dT][dT] 
Sigma Aldrich 
BRCA1 3’UTR 1 Sense: GCUCCUCUCACUCUUCAGU[dTdT] 
Antisense: [Phos]ACUGAAGAGUGAGAGGAGC[dT][dT] 
Sigma Aldrich 
BRCA1 3’UTR 2 Sense: AAGCUCCUCUCACUCUUCAGU[dT][dT] 
Antisense: [Phos]ACUGAAGAGUGAGAGGAGCUU[dT][dT] 
Sigma Aldrich 
CDK1 ON-TARGETplus SMARTpool L-003224-00-0005 Dharmacon 
PALB2 3’UTR Sense: GGAGAAUAUCUGAAUGAAUGACA [dT][dT] 
Antisense:[Phos]UGUCAUUCAGAUAUUCUCC [dT][dT] 
Sigma Aldrich 
PIN1_A Sense: GCUCAGGCCGCCGAGUGUACUA [dT][dT] 
Antisense:[Phos]UAGUACACUCGGCGGCCUGAGC [dT][dT] 
Sigma Aldrich 
PIN1_B Sense: GAAGACGCCUCGUUUGCGC [dT][dT] 
Antisense:[Phos] GCGCAAACGAGGCGUCUUC [dT][dT] 
Sigma Aldrich 
  
Supplementary Table 3 - Details of inhibitors  
Inhibitor Company Catalogue 
Number 
Target Concentration  
4AN Sigma-Aldrich A0966 PARPi 1-20 µM 
Aphidicolin Sigma-Aldrich A0781 DNA polymerase α 5-100 nM 
Cisplatin Sigma-Aldrich PHR1624 DNA-crosslinker 1-5 µM 
CldU Sigma-Aldrich C6891 Thymidine analogue 250 µM 
Colcemid Gibco 15212012 Microtubule poison 0.05 µg/ml 
EdU Thermofisher A10044 Thymidine analogue 10 µM 
GSK Inhibitor IX MERCK-Millipore 361552 GSKα/β 5 µM 
Hydroxyurea Sigma-Aldrich H8627 Ribonucleoside reductase 1-10 mM 
IdU Sigma-Aldrich I7125 Thymidine analogue 25 µM 
INDY MERCK-Millipore 405273 DYRK 20 µM 
Juglone Sigma-Aldrich H47003 PIN1 20 µM 
MG132 Sigma-Aldrich 474787 Proteasome inhibitor 5 µM 
Mirin Sigma-Aldrich M9948 MRE11 50 µM 
Olaparib Selleckchem S1060 PARPi 1-20 µM 
RO-3306 Selleckchem S7747 CDK1/2 5 µM 
Roscovitine Sigma-Aldrich R7772 CDK1/2 25 µM 
SP600125 Selleckchem S1460 JNK1/2 25 µM 
U0126 Selleckchem S1102 MEK1/2 10 µM 
Veliparib Selleckchem S1004 PARPi 1-20 µM 
 
  
Supplementary Table 4 - Antibody Table 
Antibody (clone) Host Supplier Cat. number Lot number Technique Conc RRID 
β-actin Rabbit Abcam Ab8227 GR3215935-1 WB 1:3000 AB_2305186 
BARD1 Rabbit Abcam ab226854 GR3197067-8 WB 1:2000  
BRCA1 (D-9) Mouse Santa Cruz Sc6954 C2519 IF 1:500 AB_626761 
BRCA1 (MS110) Mouse MERCK Millipore OP94 3091924 WB 1:500 AB_213438 
pS114-BRCA1 (3C10G8) Mouse Genscript  Custom design  WB 1:1000  
pS114-BRCA1 Rabbit Genscript  Custom design  WB/PLA 1:1000  
CDK1 (A17) Mouse Abcam Ab18 GR133813-4 WB 1:2000 AB_2074906 
CldU (BrdU) Rat Abcam Ab6326 GR3173537-9 Fibres/IF 1:2000 AB_305426 
Flag (M2) Mouse SigmaAldrich F1804 SLBT7654 WB 1:1000 AB_262044 
IdU (BrdU) Mouse BD Biosciences 347580 8151735 Fibres 1:500 AB_400326 
γH2AX Rabbit Abcam Ab2893 GR3242597-1 IF 1:2000 AB_303388 
PALB2 Rabbit Bethyl A301.246A  WB 1:2000 AB_890607 
PIN1 Mouse R&D Systems MAB2294  WB 1:1000 AB_2163944 
RAD51 (H-92) Rabbit Santa Cruz SC8349 E0616 WB/IF 1:1000 AB_2253533 
RAD51 (Ab-1) Rabbit Calbiochem PC130 3135376 PLA 1:100 AB_2238184 
Tubulin Mouse Santa Cruz sc-5286 H0613 WB 1:5000 AB_628411 
Vinculin [EPR8185] Rabbit Abcam Ab129002 GR221671-50 WB 1:2000 AB_11144129 
BrdU-Biotin Mouse Jackson Immunoresearch 200-002-211 134961 PLA 1:100 AB_2339006 
BrdU-Biotin Rabbit Bethyl A150-109A  PLA 1:100 AB_67327 
Donkey α Mouse AlexaFluor 488 Donkey Life technologies A21202 1975519 IF 1:5000 AB_141607 
Donkey α Rabbit AlexaFluor 488 Donkey Life technologies A21206 1874771 IF 1:5000 AB_2535792 
Donkey α Mouse AlexaFluor 555 Donkey Life technologies A31570 1774719 IF 1:5000 AB_2536180 
Donkey α Rabbit AlexaFluor 555 Donkey Life technologies A31572 1945911 IF 1:5000 AB_162543 
Donkey α rat  AlexaFluor 555 Donkey Life technologies A21434 1987272 IF 1:5000 AB_2535855 
Rabbit α Mouse HRP Rabbit Dako P0161 20062080 WB 1:10000 AB_2687969 
Swine α Rabbit HRP Swine Dako P0217 20047666 WB 1:10000 AB_2728719 
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Extended Data Figure Legends 
Extended Data Figure 1. The canonical BRCA1-PALB2 interaction is not required for fork protection 
a, Schematic of the DNA fibre assay used to measure fork protection by calculating IdU/CldU ratios  
b-c, IdU/CldU ratios from U20S cells depleted for BRCA1 or PALB2 treated with HU (5 mM, 3 hours). 
n=300 fibres from 3 biological repeats, bars=median±95% CI. Representative western blot (n=3, c). 
d, Schematic of BRCA1 protein indicating RING (red), RAD51-binding (green), coiled-coil (blue) and 
BRCT repeat (purple) domains. The M1411T patient variant disrupts PALB2 binding and is located in 
the coiled-coil domain. 
e, Schematic of PALB2 protein indicating BRCA1-interacting coiled-coil (blue), ChAM and DNA 
binding (purple and green) and WD40-like repeat (orange) domains. The ΔNT-PALB2 mutant lacks 
the N-terminal coiled-coil domain.  
f, Colony survival following cisplatin treatment (2.5 µM, 2 hours) in HeLa cells depleted for BRCA1 
and complemented with Flag-EGFP-WT-BRCA1 or Flag-EGFP-M1411T-BRCA1. Data=mean±SEM, n=4.  
g, Colony survival following cipslatin treatment (2 hours) in U20S cells depleted for PALB2 and 
complemented with Flag-WT-PALB2 or Flag-ΔNT-PALB2. Data=mean±SEM, n=4.  
h, Representative western blot for j (n=3).  
i, Representative Western blot for k (n=3) 
j, IdU/CldU ratios from U20S cells depleted for BRCA1 and complemented with WT or Flag-EGFP-
M1411T-BRCA1 and treated with HU (5 mM, 3 hours). n=300 fibres from 3 biological repeats, 
bars=median±95% CI. 
k, IdU/CldU ratios from U20S cells depleted for PALB2 and complemented with WT or Flag- ΔNT-
PALB2 and treated HU (5 mM, 3 hours). n=300 fibres from 3 biological repeats, bars=median±95% CI. 
l, The % stalled replication forks in U20S cells depleted for BRCA1 and complemented with Flag-
EGFP-WT-BRCA1 or Flag-EGFP-M1411T-BRCA1. Data=mean±SEM, n=3. 
m, As for l but depleted for PALB2 and complemented with Flag-WT-PALB2 (n=3) or Flag-ΔNT-PALB2 
(n=3). Data=mean±SEM, n=2 (NTC, siPALB2). 
n,  The % replication forks able to restart after release from HU (5 mM, 3 hours) in U20S cells 
depleted for BRCA1 and complemented with Flag-EGFP-WT-BRCA1 or Flag-EGFP-M1411T-BRCA1. 
Data=mean±SEM, n=3. 
o, As for n but depleted for PALB2 and complemented with Flag-WT-PALB2 (n=3) or Flag-ΔNT-PALB2 
(n=3). Data=mean±SEM, n=2 (NTC, siPALB2). 
All P-values derived from two-sided unpaired t-test. 
 
Extended Data Figure 2. BRCA1-BARD1 mediated fork protection requires the BARD1-RAD51 
binding domain 
a-b, Colony survival following Olaparib treatment (2 hours, n=4) (a) or HU (16 hours, n=7) (b) in U20S 
cells depleted for BARD1 and complemented with RFP-Flag-WT-BARD1 or RFP-Flag-AAE-BARD1. 
Data=mean±SEM. 
c-d, IdU/CldU ratios from U20S cells depleted for BARD1 and complemented with WT or RFP-Flag-
AAE-BARD1 and treated with HU (5 mM HU, 3 hours). n=315 fibres from 3 biological repeats, 
bars=median±95% CI. Representative western blot (n=3, d). 
e-f, As for c but complemented with WT or RFP-Flag-R99E-BARD1. n=300 fibres from 3 biological 
repeats, bars=median±95% CI. Representative western blot (n=3, f). 
All P-values derived from two-sided unpaired t-test. 
 
Extended Data Figure 3. The role of RING-proximal BRCA1-BARD1 phospho-sites in replication 
stress 
a-e, IdU/CldU ratios (a) and CldU track lengths (b,d) from U20S cells depleted for BARD1, 
complemented with RFP-Flag-BARD1 variants and treated with HU (5 mM, 3 hours). n=300 (a), n= 
600 (b) fibres from 3 biological repeats or n=290 from 2 biological repeats (d). Bars=median±95% CI. 
Representative western blots (n=3, c) (n=2, e). 
f, The percentage of co-localising BRCA1-CldU foci per cell was scored from U20S cells expressing 
Flag-EGFP-WT-BRCA1 or Flag-EGFP-S114A-BRCA1. n=25 cells, bars=median±95% CI. ns=not 
significant. 
g, Representative blot of Flag immunoprecipitation of Flag-EGFP-BRCA1 variants from HEK293 cells 
(n=3).  
h-i, As for b, but depleted for BRCA1 and complemented with Flag-EGFP-S114A-BRCA1 and treated 
with Mirin (50 μM) and HU (5 mM) for 3 hours. n=245 fibres from 3 biological repeats, 
bars=median±95% CI. Representative western blot (n=3, i).  
All P-values derived from two-sided unpaired t-test. 
 
Extended Data Figure 4. Phosphorylation of BRCA1 at serine 114 promotes PIN1 interaction 
a, Schematic of the protein structure of PIN1 indicating phospho-binding WW and Peptidyl-Prolyl-
Isomerase (PPIase) domains. Cartoons illustrate the GST-fusions of the WW domain WT and W34A 
phospho-binding mutant. Coomassie blots indicate recombinant GST-WW fragments purified from E. 
coli. 
b, Densitometry quantification of GST-WW pull downs from U20S cells expressing Flag-EGFP-WT-
BRCA1 and Flag-EGFP-S114A-BRCA1. Beads bound by GST-W34A WW-domain were used as a 
negative control from 4-independent experiments. Data=mean±SEM. All P-values derived from two-
sided unpaired t-test. Representative image shown in Fig 1e. 
c, GST-WW pull downs from U20S cells expressing Flag-EGFP-WT-BRCA1 and Flag-EGFP-S114D-
BRCA1. Beads bound by GST-W34A WW-domain were used as a negative control. Representative 
blot (n=3). 
d, As for c but with cells expressing Flag-EGFP-WT-BRCA1 and treated ± HU (5 mM, 3 hours). 
Representative blot (n=3). 
e, As for d but in HEK293 cells and probed for endogenous BRCA1. The final lane indicates lysates 
pre-treated with calf-intestinal phosphatase. Representative blot (n=3). 
f, As for c but from U20S cells expressing RFP-Flag-WT-BARD and RFP-Flag-S148A-BARD1. 
Representative blot (n=3). 
g, Table of inhibitors used to inhibit proline-directed kinases in h. 
h, GST-WW pull downs from HEK293 cells expressing Flag-EGFP-BRCA1 treated with and without 
kinase inhibitors described in g. Beads bound by GST-W34A WW-domain were used as a negative 
control. Representative blot (n=3). 
i, GST-WW pull downs from HEK293 cells expressing Flag-EGFP-BRCA1 and depleted for CDK1.  
j, Coomassie blots of purified recombinant WT and S114A His-BRCA11-300:His-BARD126-142 
(representative gel n=3). 
k, Recombinant purified His-BRCA11-300:His-BARD126-142 were incubated with recombinant active 
CDK1/Cyclin A2, CDK2/Cyclin A or CDK9/Cyclin K. Western blots were probed for phospho-S114-
BRCA1 (3C10G8) and BRCA1 (representative blot n=3).  
l, Recombinant purified WT or S114A His-BRCA11-300:His-BARD126-142 were incubated with 
recombinant active CDK2/Cyclin A. Western blots were probed for phospho-S114-BRCA1 (3C10G8) 
and BRCA1 (representative blot n=3).  
 
Extended Data Figure 5. PIN1 regulates the BRCA1-BARD1 heterodimer to promote fork protection 
a, CldU fibre tract lengths were measured from U20S cells depleted for BRCA1 and treated with HU 
(5 mM) and Juglone (20 μM) for 3 hours. n=450 fibres from 3 biological repeats, bars=median±95% 
CI. 
b-c, CldU fibre tract lengths were measured from U20S in cells depleted for BARD1 and/or PIN1 and 
treated with HU (5 mM, 3 hours). n=300 fibres from 2 biological repeats, bars=median±95% CI. 
Representative western blot (n=2, c). 
d-e, Representative blot (d) and quantification (e) of BRCA1 expression levels normalised to β-actin 
levels following PIN1 depletion from 9-biological repeats. Data=mean±SEM, n=9. n.s = not 
significant. 
f-g, IdU/CldU ratios from U20S cells depleted for BRCA1 and complemented with Flag-EGFP-BRCA1 
variants and treated with HU (5 mM, 3 hours). n=200 fibres from 2 biological repeats, 
bars=median±95% CI. Representative western blot (n=2, g).  
All P-values derived from two-sided unpaired t-test. 
 
Extended Data Figure 6. BRCA1-BARD1 isomerisation enhances RAD51 binding  
a, WT and S114D His-BRCA11-500 and BARD127-327 incubated with full length GST-PIN1 to induce 
isomerisation. His-BRCA1-BARD1 complexes were then incubated with recombinant active RAD51 
and their ability to bind RAD51 was assessed by His-purification of the complex followed by western 
blot. Representative image (n=2). 
b, Representative Coomassie gel of recombinant purified full length WT and C113S GST-PIN1 from E. 
coli (n=2). 
c, Representative Coomassie gel of recombinant purified His-BRCA11-500 and BARD127-327 from E. coli. 
(n=3). 
d, Recombinant RAD51 incubated with recombinant full length BRCA1-BARD1 mutants in the 
presence of ATP and Mg2+. The ability of BRCA1-BARD1 to bind RAD51 was assessed by Strep-pull 
down of BRCA1 followed by SDS-PAGE and Coomassie staining (n=2). 
e, Quantification of recombinant RAD51 bound to recombinant full length BRCA1-BARD1 and P115A-
BRCA1-BARD1 mutant in the presence of ATP and Mg2+, normalised to the respective amount of 
BRCA1 and BARD1 and given relative to WT BRCA1-BARD1 to indicate fold 
change. Data=mean±SEM. n=6 (2 biological repeats each with 3 technical repeats). 
f-g, Quantification of amount of RAD51 co-immunoprecipitated with Flag-EGFP-BRCA1 and RFP-Flag-
BARD1 from HEK293 cells, normalised to BRCA1-BARD1 levels precipitated. Data=mean±SEM, n=12. 
Representative image (g).  
h, Representative gel for recombinant full length BRCA1-BARD1 incubated with trypsin and samples 
taken at the times indicated. The limited proteolysis profiles were assessed by SDS-PAGE and 
Coomassie staining. n=3. 
i, Representative images for Fig 3e. RAD51 co-localisation with nascent DNA, marked by pulse 
labelling with EdU, was measured using the proximity ligation assay (PLA) in U20S cells depleted for 
BRCA1 and complemented with Flag-EGFP-BRCA1 variants as indicated. Red foci indicate 
RAD51/EdU-Biotin interaction in cells. Scale bars=10 µm. 
All P-values derived from two-sided unpaired t-test.  
 
Extended Data Figure 7. BRCA1-S114A shows increased sensitivity to replication stress agents 
a-d, Colony survival following treatment with Aphidicolin (16 hours) (a) or PARP inhibitors (2 hours) 
Olaparib (b), Veliparib (c) and 4AN (d) was measured in HeLa cells depleted for BRCA1 and 
complemented with Flag-EGFP-WT-BRCA1 or Flag-EGFP-S114A-BRCA1. Data=mean± SEM, n-values 
given in brackets for each condition.  
e, Colony survival following 16-hour treatment with HU was measured in U20S cells depleted for 
BRCA1 and complemented with WT or S114A Flag-EGFP-BRCA1. Data=mean± SEM, n=3.  
f-g, RAD51 foci in S-phase U20S cells marked by EdU were scored from BRCA1 depleted cells 
complemented with Flag-EGFP-WT-BRCA1 or Flag-EGFP-S114A-BRCA1 treated with 20 µM Olaparib 
(2 hours). Representative images with scale bars = 10 μm (f). Graph shows number of RAD51 
foci/EdU-positive cell (g). Bars=median±95% CI, n-values given in brackets for each condition. P-value 
derived from two-sided unpaired t-test. 
 
Extended Data Figure 8. Constitutive expression of Flag-EGFP-P115A-BRCA1 promotes DNA 
damage 
a, U20S cells induced to constitutively express Flag-EGFP-WT-BRCA1 or Flag-EGFP-P115A-BRCA1 
were stained for γH2AX foci as a marker for DNA damage accumulation over time. γH2AX foci were 
scored from EdU negative cells. Combined data from 3-biological repeats. n=90 cells. 
Bars=mean±SEM. P-value derived from two-sided unpaired t-test. 
 
Extended Data Figure 9. Patient variants define a novel region of BRCA1 required for fork 
protection 
a, Colony survival following 2 hour treatment with Olaparib was measured in cells depleted for 
BRCA1 and complemented with WT or Flag-EGFP-BRCA1 variants (Y101N, Y179C, S184C, S265Y in 
U20S; S114P and R133C in HeLa). Data=mean±SEM. n-values given in brackets for each condition 
b-c, As for a, but with continuous treatment of Olaparib (b) or cisplatin (c) and all patient variants 
are in U20S cells.  
d-e, RAD51 foci formation was scored at 2 hours following 2 Gy IR in U20S cells depleted for BRCA1 
and complemented with WT or patient variant Flag-EGFP-BRCA1 as indicated. Representative images 
for e. Scale bars=10µm (d). Graph scored n=150 cells from 3 biological repeats. Bars=median±95% CI 
(e). All P-values derived from two-sided unpaired t-test.  
 
Extended Data Figure 10. Patient variants define a novel region of BARD1 required for fork 
protection 
a, Colony survival following 2 hour treatment with Olaparib was measured in U20S cells depleted for 
BARD1 and complemented with WT or patient variant RFP-Flag-BARD1 as indicated. 
Data=mean±SEM. n-values given in brackets for each condition 
b-c, As for a but with continuous treatment with Olaparib (b) or cisplatin (c). 
d-e, RAD51 foci formation was scored at 2 hours following 2 Gy IR in U20S cells depleted for BARD1 
and complemented with WT or patient variant RFP-Flag-BARD1 as indicated. Representative images 
(d). Scale bars=10µm. Graphed data is combined from 3-biological repeats (e). Actual n-values for 
each condition given in brackets. Bars=median±95% CI.  
f, HR (U2OS DR3-GFP) assays using siBARD1 or siNTC treated cells transfected with I-SceI and RFP, or 
RFP-Flag-BARD1 constructs shown and counted by FACS analysis. GFP+ cells were normalised to RFP-
positive cells as a measure of transfection efficiency. %-repair is given relative to siNTC. 
Data=mean±SEM, n=6. Gating strategy is describe in Supplemental Figure 1. 
All P-values derived from two-sided unpaired t-test. 
 
Extended Data Figure 11. Isomerisation of phospho-BRCA1-BARD1 promotes replication fork 
protection 
Model to illustrate CDK1/2 (grey) phosphorylation at S114 (red) and subsequent PIN1 (purple) 
isomerisation events on BRCA1 (green) and BARD1 (orange).  BRCA1 isomerisation enhances the 
ability of BARD1 to associate with RAD51 (brown) to promote replication fork protection 
 
Extended Data Table 1. DNA damage survival and fork protection responses by BRCA1-BARD1 
variants  
A summary of the main findings from this study. 
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